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1 LIVER RESECTION FOR INTRAHEPATIC
CHOLANGIOCELLULAR CARCINOMA (ICC)
Lang H, Sotiropoulos G, Brokalaki E, Fru¨hauf NR, Kaiser G,
Paul A, Malago´ M, Broelsch CE, Klinik fu¨r Allgemein- und
Transplantationschirurgie, Universita¨tsklinikum Essen,
Essen, Germany
INTRODUCTION AND AIM: Intrahepatic cholangiocarcinoma
(ICC) is supposed to be associated with an extremely poor prognosis.
Since ICC is currently considered a contraindication for liver trans-
plantation and results of chemotherapy are poor surgical resection
remains the only chance for cure. PATIENTS AND METHODS:
Data of 120 patients who underwent explorative laparoscopy/
laparotomy for ICC between 04/98 and 06/2004 were evaluated with
regard to operative data, pathologic findings and outcome measured
by survival and recurrence rate. RESULTS: In 53 patients liver
resection was possible (resectability rate 44%). There were 39
extended hepatectomies, 6 left or right hepatectomies and 8 mono-
or bi-segmentectomies. In addition the following procedures were
performed: resection of hilar bifurcation (n=18), partial resection
of vena cava (n=4), portal vein (n=8), major hepatic vein (n=2) or
hepatic artery (n=1). There were 30 R0, 20 R1 and 3 R2 resections.
30-day mortality was 5/53 (9.4%). Following resection the calculated
1-/3-/5-year-survival is 62%/42%/28%, respectively, with a median
survival of 26 months. After R0 resection the calculated 1-/3-/5-year-
survival is 81%/66%/53% compared with 37%/11%/0% after R1/2
resection (p50.0001;logrank). At a median follow-up of currently
18 months (range 0–65 months) tumor recurred in 15/30 patients
(50%) after a median time of 12 months after R0 resection (range
2–34 months). CONCLUSION: The presented data show that an
R0 resection offers a chance for long-term survival even in large and
advanced intrahepatic cholangiocarcinoma. With regard to the high
rate of explorations only and the poor results after incomplete
(R1/2) resection an improved pre- and intra-operative assessment of
resectability is of utmost importance.
2 CELECOXIB INDUCES EARLY MITOCHONDRIA
AND CASPASES MEDIATED APOPTOSIS IN
HEPATOCELLULAR CARCINOMA CELL LINES
Haugg AM, Koch A, Lorenz K, Hill P, Schirmacher P, Mu¨ller M,
Kern M, Internal Medicine IV, University of Heidelberg,
Heidelberg, Germany
INTRODUCTION AND AIM: The prostaglandin metabolism
central enzyme COX-2 is prevalently dysregulated in hepatocellular
carcinoma (HCC). We have recently demonstrated that selective
COX-2 inhibitors (Celecoxib) suppress growth of human HCC-cells
in vivo and in vitro by inducing apoptosis via cytochrome-c release
and consequently execution of caspase (79,73,76) cascade. Our
interest was further analysis of proapoptotic signalling mechanisms
caused by selective COX-2 inhibition in HCC cell lines. PATIENTS
AND METHODS: We performed our studies with the selective
COX-2 inhibitor Celecoxib in HuH7 and HepG2 cell lines. Moni-
toring of cell viability and apoptosis were performed by MTT
and FACS analysis (Nicoletti staining). Signalling relevant caspase
proteins were analysed by Western immunoblot. The function of
caspases was confirmed by general (Z-VAD-FMK) and specific
caspase inhibitors. RESULTS: Celecoxib induced apoptosis in both
cell lines in a time- (within 12 h) and dose- (100 mM) dependent
manner. Significant change of mitochondrial membrane potential
was demonstrated by two independent stainings (DIOC and JC-1).
In addition to the consecutive cytochrome-c release and following
activation of effector caspase-cascade time correlated (2 h) upstream
cleavage of initiator caspase-8 was noticed. General and specific
caspase73,78 and79 -inhibitors could retract Celecoxib-induced
apoptosis up to 70%. CONCLUSION: Our studies showed the
functional relevance of initiator and effector caspase signalling in
rapid mitochondrial pathway-mediated apoptosis induced by selec-
tive COX-2 inhibition in HCC cell lines. These results may lead to
new therapeutic strategies.
3 SYNERGISTIC EFFECTS OF THE P53 FAMILY
MEMBERS P53, P63 AND P73 WITH CHEMOTHERAPEUTIC
DRUGS OPEN UP NEW STRATEGIES IN
HEPATOCELLULAR CARCINOMA TREATMENT
Schulze Schleithoff E2, Schulze-Bergkamen H1, Lorenz K2,
Krammer P3, Stremmel W2, Mu¨ller M, Koch AF2, (1) Medical
Department, University of Mainz, Mainz, Germany; (2) Department
of Internal Medicine IV, University of Heidelberg, Heidelberg,
Germany; (3) Tumor Immunology Program, DKFZ, Heidelberg,
Germany
INTRODUCTION AND AIM: It was shown that p63 and p73 are
required for p53- dependent apoptosis (Flores et al., Nature, 2002)
suggesting the existence of a complex network of interaction between
the p53 family members. The aim of our study was to investigate
the interaction of p53, p63 and p73 to explore mechanisms of
resistance to chemotherapy. PATIENTS AND METHODS: Hep3B
(p537/7) cells were infected with rAd5CMV-p53, -p63, -p73 or
-GFP alone or in combination. The additive effect of chemotherapy
was examined. The apoptosis pathways were investigated by
FACS analysis, luciferase reporter assays and cDNA microarrays.
RESULTS: Adenoviral transfer of p53, p63 and p73 alone resulted
in apoptosis induction. Combined transfer of p53 family members
had a synergistic effect. Additional treatment with bleomycin led to
a significant increase of apoptosis rates. Luciferase reporter assays
showed that combined transfer of p53, p63 and p73 was more
effective in transactivating both the CD95 gene and the Bax gene.
In addition, transfer of p53 family members led to a depolarisation
of mitochondrial membrane. Using microarray analysis we identified
death receptors (CD95, TRAIL-R1, 2), caspases (73, 76 and 8)
and mitochondrial genes (BIK, BIM, RAD9) as target genes of
p53 family members. CONCLUSION: Following adenoviral trans-
fer, p53 family members engage both extrinsic and intrinsic apoptosis
pathways in the cell, death receptor dependent and mitochondrial
apoptosis. Combined transfer of p53 family members led to a sig-
nificantly better response of hepatoma cells towards chemotherapy.
The knowledgeof the complex interplaybetween p53 familymembers
is important to develop new anticancer strategies.
4 SURGERY FOR HEPATOCELLULAR CARCINOMA:
ROLE OF CONCOMITANT CIRRHOTIC DISEASE
Gassmann P, Bara F, Haier J, Krieglstein CF, Senninger N,
Department of General Surgery, University Hospital Muenster,
Muenster, Germany
INTRODUCTION AND AIM: Beside liver transplantation, liver
resection is the only potentially curative therapy for hepatocellular
carcinoma (HCC). However, this is often precluded by poor liver
function due to accompanying cirrhosis. The question whether liver
cirrhosis should preclude all patients from liver resection is currently
under discussion. The aim of our study was therefore to determine
the role of cirrhotic liver disease in the operative outcome and survival
after liver resection for HCC. PATIENTS AND METHODS:
All 78 patients who underwent laparotomy with ‘intention to treat’
between January 1997 and December 2003 were reviewed. Patients
who underwent potentially curative resection were divided into two
groups: 1. LC: with liver cirrhosis and 2. WOLC: without liver
cirrhosis or fibrosis. The primary endpoint was patient survival
(Kaplan-Maier method, log-rank test), secondary endpoints were
surgical complications. RESULTS: In 31 patients (40%) (male:
female=25 : 6) 33 resections with clear surgical resection margins
were achieved (R1: 5 cases [13%], R0: 28 cases [87%]). 18 cases
(Child A: 14, Child B: 4) were included in the LC group and 15 cases
(45%) were included in the WOLC group. Unifocal lesions were
found in 28 and multifocal lesions were found in 5 cases. The median
resected volume did not differ significantly between the two groups
(LC: 37% [5–75%] vs WOLC: 45% [5–75%]). In the LC-group
we experienced 6 (33.3%) and in the WOLC 4 (26.7%) major
complications. One patient died in each group. The median survival
was similar for both groups (LC: 30 [1–70] months vs. WOLC: 42
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[1–100]). One patient with R1 resection survived more than 60
months. CONCLUSION: This study demonstrates that liver
resection for HCC can be performed safely in patients with cirrhotic
liver disease. Perioperative mortality and morbitity of liver surgery
was not significantly influenced by liver cirrhosis. Also long-term
survival rates were not affected by the concomitant liver cirrhosis.
5 INFLAMMATORY PSEUDOTUMOR OF THE LIVER
(IPL): AN UNUSUAL PATHOLOGY
Sa´nchez Claria´ R, de Santiban˜es E, Palavecino M, Pekolj J,
Hepato-Pancreato-Biliary Surgery and Liver Transplantation,
Buenos Aires, Argentina
INTRODUCTION AND AIM: IPL is an infrequent pathology
with a few cases reported in the literature. IPL has an uncertain
origin and the final diagnosis is the definitive anatomopathological
report. The aim of this study is to describe the experience in a high
volume center in hepato-pancreato-biliary surgery. PATIENTS
AND METHODS: Between 1980 and 2004, we performed 1070
hepatectomies, 9 of them to treat IPL. Mean age was 40 years
(r: 6–66). The most frequent clinical presentation was fever and
abdominal pain. Most patients had elevated VSG and negative
tumoral markers. RESULTS: Six right hepatectomies and three
left hepatectomies were performed. Mean tumor size was 10 cm
(r: 5–19). Tumors seemed like a malignant tumor with areas of
haemorrhagic necrosis. The final anatomopathological study re-
ported in all cases an IPL. Morbidity was 18%. Three patients died
(one because of postoperative complications, another died 7 years
after the resection with a lymphoma and the last one died 3 years
later with a carcinomatosis secondary to a gastric adenocarcinoma).
The other six patients are alive and have no evidence of tumoral
recurrence. CONCLUSION: IPL is a rare liver disease. As it is
difficult to diagnose it only with a fine needle biopsy and a malingnant
tumor cannot be ruled out, the surgical resection is the best treat-
ment for these patients.
6 LOCAL RECURRENCE AFTER HEPATIC
RADIOFREQUENCY COAGULATION – MULTIVARIATE
META-ANALYSIS AND REVIEW OF CONTRIBUTING
FACTORS
Mulier S2, Ni Y1, Jamart J2, Ruers T3, Marchal G1, Michel L1,
(1) Department of Radiology, University Hospital Gasthuisberg,
Catholic University of Leuven, Leuven, Belgium; (2) Department
of Biostatistics, University Hospital Mont-Godinne, Catholic
University of Louvain, Yvoir, Belgium; (3) Department of Surgery,
University Medical Centre Nijmegen, Nijmegen, The Netherlands
INTRODUCTION AND AIM: Local recurrence rate after radio-
frequency coagulation of liver tumors varies widely between 2 and
60%. Apart from tumor size as an important risk factor for local
recurrence, little is known about the impact of other factors. The
purpose of this study was to analyse the factors that influence local
recurrence. PATIENTS AND METHODS: An exhaustive literature
search was carried out for the period from 1 January 1990 to 1 January
2004. Only series with a minimal follow-up of 6 months and/or mean
follow-up of 12 months were included. Uni- and multivariate meta-
analyses were carried out. RESULTS: Ninety-five independent
series were included, allowing the analysis of the local recurrence
rate of 5224 treated liver tumors. In a univariate analysis, tumor-
dependent factors with significantly less local recurrences were:
smaller size, neuroendocrine metastases, non-subcapsular location
and location away from large vessels. Physician-dependent favor-
able factors were: surgical (open or laparoscopic) approach, vascular
occlusion, general anesthesia, a 1-cm intentional margin and a
greater physician experience. In a multivariate analysis, signifi-
cantly less local recurrences were observed for small size (p50.001)
and a surgical (versus percutaneous) approach (p50.001).
CONCLUSION: Radiofrequency coagulation by laparoscopy or
laparotomy results in superior local control, independent of tumor
size. The percutaneous route should mainly be reserved for patients
who cannot tolerate a laparoscopy or laparotomy. The short-term
benefits of less invasiveness for the percutaneous route do not
outweigh the longer-term higher risk of local recurrence.
7 EXTENDED RESECTIONS FOR INTRAHEPATIC
CHOLANGIOCELLULAR CARCINOMAS
Benckert C, Thelen A, Schumacher G, Neuhaus P, Jonas S,
General-, Visceral- and Transplantation Surgery, Humboldt
Universitaet, Charite, Campus Virchow Clinic,
Universitaetsmedizin Berlin, Berlin, Germany
INTRODUCTION AND AIM: Surgical resection of cholangio-
cellular carcinoma (CCC) is the only therapy with a curative
intention. In contrast to hepatocellular carcinoma (HCC), CCC is
only rarely associated with liver cirrhosis. Therefore, extended
resections are also feasable and locally advanced tumors resectable.
PATIENTS AND METHODS: From 1988 to 2002, 2051 patients
underwent hepatic resection in our institution, among these were
84 patients (4%) suffering from CCC. The surgical procedures
in these patients were wedge resections (5%), hemihepatectomies
(42%), extended resections (33%) and trisectionectomies (20%).
RESULTS: The postoperative mortality (90 days) was 8% in all
patients, 3% after hemihepatectomy, 12% after extended resection
and 14% after trisectionectomy. The rate of formally curative
resections (R0) was 59%. The 1-, 5- and 10-year survival rates after
R0 resection were 64%, 38% and 34%, respectively. The respective
rates after R1 and R2 resections were significantly lower. The
histopathological differentiation was moderate in most CCC (G2:
67%). Highly differentiated tumors (G1) occurred in 4 patients, and
poorly differentiated tumors in 28 patients. All patients suffering
from G1 tumors survived over the long term up to 14 years,
compared to 10-year survival rates of 34% in patients with G2 tumors
and one patient with a G3 tumor. CONCLUSION: Extended
resections had been perormed in more than half of the patients with
an acceptable postoperative risk. In CCC, biological properties
such as the histopathological differentiation have a major impact
on the postoperative outcome.
8 LATE SURVIVAL AFTER SURGICAL RESECTION
OF PRIMARY LIVER MALIGNANCIES IS LINKED TO
UNDERLYING CHRONIC LIVER DISEASE
Hubert C5, Sempoux C1, Rahier J1, Horsmans Y2, Geubel A2,
Van Beers B3, Liebe A3, Zech F4, Leonard D5, Gigot JF5, (1)
Pathology; (2) Gastro-Enterology; (3) Radiology; (4) Internal
Medicine; (5) Hepatobiliopancreatic Surgery, St-Luc University
Hospital, Brussels, Belgium
PATIENTS AND METHODS: 65 patients suffering from hepato-
cellular carcinoma (HCC) (Group I: n=55) and CCC (Group II:
n=10) underwent surgical resection. Group I was subdivided into
HCC on normal liver (Group I-A: n=29) and HCC on chronic liver
disease (CLD) (Group I-B: n=26). Patients’ clinical data and
tumour features were not different in all groups, except for median
patients’ age and ASA status, which were significantly greater in
group I-B. Radical liver resection was obtained in 96% and 90% of
HCC and CCC. Four HCC patients underwent associated radio-
frequency thermoablation for contralateral or multiple lesions. Types
of liver resections included major hepatectomies in 45% and 70% of
HCC and CCC (NS). RESULTS: 60-day mortality was 0% in
Group I-A and Group II and 4% in Group I-B (NS). The 5-year
overall (OS) and disease-free survival (DFS) rates were respectively
54.9% and 35% in HCC and 60% and 49% in CCC patients (NS).
However, the 5-year OS and DFS were 71% and 59% in Group I-A
and 37% and 6% in Group I-B. Multivariate statistical analysis
demonstrated in HCC patients that chronic liver disease, poor
differentiation, satellite nodules and male sex were significant adverse
predictive factors of survival. CONCLUSION: Surgical resection for
primary liver cancers is safe and effective with attractive OS and DFS,
except when associated with underlying CLD, which is the worst
prognostic factor of bad outcome.
9 SURGICAL THERAPY OF BENIGN LIVER TUMOURS:
A ONE-CENTRE EXPERIENCE.
Angele MK, Radaj A, Jauch KW, Lo¨he F, Klinikum Grosshadern,
Ludwig-Maximilians University, Department of Surgery,
Munich, Germany
INTRODUCTION AND AIM: The wide use of imaging devices,
i.e. ultrasound, CT, etc., as diagnostic tools for the treatment of
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abdominal pain leads to an increased detection of benign liver
tumours. Diagnostic and therapeutic approaches to benign liver
tumours are still under debate. The aim of the study was to report
our results on surgical treated benign liver tumours. PATIENTS
AND METHODS: A total of 111 patients with the diagnosis of a
benign liver tumour were retrospectively evaluated (1990–2004).
In this time 113 resections were performed (85 females, 26 males,
age 45.1+/7 13.5 years). Indication for surgical intervention was
based on tumour-associated complaints or lesions suspicious for
adenoma. RESULTS: 22 laparoscopic and 91 open liver resections
were performed. Lethality and morbidity were found to be 0% and
11%, respectively. FNH (n=53), haemangioma (n=39), adenoma
(n=16) and HCC (n=3) were identified in the histological exam-
ination. Sensitivity and specificity of preoperative diagnostics were
found to be 0.59–0.89 and 0.68–0.97, respectively. Those values
were not significantly improved within the last 2 years despite the use
of special MRI examinations. CONCLUSION: Our results suggest
that the preoperative discrimination between FNH and adenoma is
still difficult. Thus, surgical resection should be indicated rather
generously for benign liver tumours as HCC was found in 3 patients
despite the preoperative diagnosis of adenoma. Contrast material-
enhanced ultrasound in combination with modern MRI scans
might increase the specificity of preoperative diagnosis of benign
liver tumours, thereby decreasing the necessity for surgical inter-
ventions in the future.
10 HEPATIC HEMANGIOMAS AND SYMPTOMS.
IS THERE A CORRELATION WITH SIZE?
Erdogan D, Busch OR, Bennink RJ, van Delden O, Gouma DJ,
van Gulik TM, Department of Surgery, Academic Medical
Center-University of Amsterdam, Amsterdam, The Netherlands
INTRODUCTION AND AIM: Hepatic hemangiomas are the
most common benign tumors of the liver and are frequently detected
because of increasing use of imaging methods. The indications for
surgical resection still remain controversial and are poorly defined.
The aim of this study was to examine correlation of tumor size
with the presence of symptoms. PATIENTS AND METHODS:
From June 1991 to October 2004, a total of 29 patients (7 men and
22 women, mean age of 48.8 (range 29–75) years) were referred for
management of a hemangioma. RESULTS: Ultrasonography
established the diagnosis of hemangioma in 13/19 (68%), 4-phase
computed tomography in 14/17 (82%) and 99mTc-Red blood cell
scintigraphy in 8/10 (80%). A total of 18 patients without complaints
were observed without complications. Nine patients (82%) under-
went surgery because of symptoms, of which one showed an increase
in tumor size from 11 to 13 cm. The mean follow-up until resection
was 34 months (range 4–96). Two patients underwent resection
because of suspected malignancy. The mean resected tumor
diameters were significantly greater when compared to non-resected
(10.3 cm (median 8, range 2–20) vs 4.1 (2.2, 1.3–11); p=0.002).
The resected tumor size in patients with symptoms was significantly
greater than the non-resected (12.5 cm (12.5, 7–20) vs 3.9 cm (2.9,
1.3–10); p=0.001). CONCLUSION: In patients with no or minimal
symptoms observation is justified. The indications for resection are
symptoms in hemangiomas larger than 4 cm or increasing size during
follow-up.
11 PERCUTANEOUS AND SURGICAL
RADIOFREQUENCY ABLATION (RFA) FOR LIVER
MALIGNANCIES: A DIFFERENT PHILOSOPHY OF
TREATMENT?
Hubert C1, Gras J1, Goffette P2, Grajeda JM1, Van Beers B2,
Liebe A2, Horsmans YI3, Sempoux C4, Rahier J4, Zech F5,
Gigot JF1, (1) Hepatobiliopancreatic Surgery; (2) Radiology,
Hepatobiliopancreatic Surgery; (3) Gastro-Enterology; (4)
Pathology; (5) Internal Medicine, St-Luc University Hospital,
Brussels, Belgium
PATIENTS AND METHODS: Sixty-five patients underwent
RFA technique through a percutaneous (Group I: 33 patients) or
a surgical approach (Group II: 32 patients). The two groups are
different according to type of disease selection (more hepatocellular
carcinoma in Group I and liver metastases in Group II) and tumour
features (smaller size but greater number of lesions in Group II). The
RFA technique was more radical in Group II, with a greater number
and a longer duration of RFA applications. In Group II, liver
resection was associated in 23 patients (72%) (including 5 patients
with RFA-assisted wedge liver resections), in order to increase
resectability. RESULTS: The 60-day postoperative mortality and
complication rates were low and not significantly different in both
groups. The postoperative hospital stay was longer in Group II.
During a median follow-up of 24 months in Group I and 21 months
in Group II, the in situ recurrence rate was 41.4% and 9.1%,
respectively (p50.001). Multivariate statistical analysis demon-
strated that tumour size 42 cm and type of approach for RFA
technique (percutaneous versus surgical) were independent pre-
dictive factors of in situ liver tumour recurrence. CONCLUSION:
RFA is a safe technique for treating liver malignancies. Differences in
results in both approaches are explained by differences in treatment
philosophy, technical conditions and tumour size selection.
12 BILIARY CYSTADENOMA AND
CYSTADENOCARCINOMA OF THE LIVER
Lee JH2, Choi DH1, Lee KG2, Park HK2, Lee KS2, (1) General
Surgery, Soonchunhyang University, Asan, South Korea;
(2) General Surgery, Hanyang University, Seoul, South Korea
INTRODUCTION AND AIM: Cystic neoplasms are rare. Biliary
cystadenoma and cystadenocarcinoma constitute less than 5% of
intrahepatic cysts of bile duct origin. Biliary cystadenoma affected
mainly women, which was a different characteristic from biliary
cystadenocarcinoma. Clinicopathological and radiological findings
are important for diagnosis and treatment of intrahepatic biliary
cystadenoma and cystadenocarcinoma. The aims of this study
were to determine the clinical and pathological aspects, treatment
and prognosis of biliary cystadenoma and cystadenocarcinoma.
PATIENTS AND METHODS: We reviewed the clinical records
of six patients with intrahepatic biliary cystadenoma and cystadeno-
carcinoma who had undergone operation from January 1986 to
June 2002 at Hanyang University Hospital. RESULTS: Primary
biliary cystadenoma and cystadenocarcinoma of the intrahepatic
biliary systems are rare. There were no specific symptoms and
signs. Diagnosis was usually done by abdominal CT and abdominal
ultrasonography. They are usually large, multilocular and cystic in
appearance. Pathologic findings revealed multiple cystic mass lined
with cuboidal to columnar epithelium. Cystic fluid nature was
usually mucous type. Of 6 patients in whom the lesion was com-
pletely excised 4 patients are alive. The other two patients died of old
age and distant metastasis. CONCLUSION: Surgical resection with
normal liver parenchyma was the only curative method. If the tumor
is confined in the liver, complete surgical excision yields excellent
prognosis. Complete resection of a biliary cystadenoma and radical
resection of a biliary cystadenocarcinoma seem to offer a chance for
long-term survival.
13 THE ROLE OF FDG-PET IN EVALUATION
OF HEPATOCELLULAR CARCINOMA
Heuer M, Frilling A, Liu C, Mu¨ller S, Ku¨hl H, Broelsch CE,
General Surgery and Transplantation, University Hospital Essen,
Essen, Germany
INTRODUCTION AND AIM: To assess the utility of 2-[18F]-
fluoro-2-deoxy-D-glucose (FDG) positron emission tomography
(PET) to detect hepatocellular carcinoma (HCC) and to evaluate
the biologic character of this malignant entity. PATIENTS AND
METHODS: We prospectively studied 51 patients with HCC who
underwent FDG-PET imaging between November 2001 and July
2004. Of them, 32 patients had underlying cirrhosis. Thirty-one
HCCs were primary and 20 were recurrent. FDG-PET scans were
visually interpreted and analysed with the standard uptake value
(SUV). The SUV ratio between tumor and background (SUV T/B
ratio) was calculated. A hepatic lesion was defined as HCC when
SUV T/B ratio was more than 1.4. Tumor biopsy or resection
specimens were available for review from each patient. RESULTS:
In 22 of 51 patients (43.1%) HCC accumulated FDG. While none
of the well differentiated HCC showed pathologic FDG uptake,
55.6% of moderately differentiated HCC and 100% of the poorly
differentiated HCC had increased uptake of FDG. The sensitivity of
FDG-PET was related to the AFP level (4400 ng/ml), maximal
tumor diameter (45 cm), and the presence of underlying cirrhosis
(normal versus cirrhotic parenchyma). The patients with HCC
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without increased uptake of FDG had longer median survival (15
months) than those harbouring HCCs with increased FDG uptake
(11 months). CONCLUSION: The role of FDG-PET in detection
of HCC, particularly in cirrhotic liver is limited. However, it presents
a useful tool in the evaluation of the biological character of HCC and
might be helpful to estimate the prognosis of the patient.
14 THE PROTEASOME INHIBITOR BORTEZOMIB
SENSITIZES HEPATOCELLULAR CARCINOMA CELLS
BUT NOT PRIMARY HUMAN HEPATOCYTES FOR
TRAIL-INDUCED APOPTOSIS
Koschny R3, Ganten TM1, Bu¨chler P2, Stremmel W1, Walczak H3,
(1) Department of Internal Medicine, University of Heidelberg; (2)
Department of Surgery, University of Heidelberg; (3) Department
of Apoptosis Regulation, DKFZ Heidelberg, German Cancer
Research Center (DKFZ), Heidelberg, Germany
INTRODUCTION AND AIM: Therapy and prognosis of hepato-
cellular carcinoma (HCC) are still limited. The TNF-related
apoptosis-inducing ligand, TRAIL, has been shown to selectively
induce apoptosis in tumor cells but not in most cell types. TRAIL-
resistant tumor cells can be sensitized for TRAIL-induced apoptosis
by pre-treatment with several conventional chemotherapeutic drugs.
Bortezomib is a member of a new family of chemotherapeutic
drugs which act in a p53-independent manner by inhibition of the
proteasome, an intracellular multiprotein complex that is important
for protein degradation. We investigated whether the proteasome
inhibitor Bortezomib (PS-341), which has been shown to sensitize
colon cancer cells for TRAIL-induced apoptosis, may be suitable for
a combination with TRAIL for the treatment of HCC. PATIENTS
AND METHODS: PS-341 and medium pre-treated human HCC
cell lines and cultured primary human hepatocytes were incubated
with TRAIL for 16 hours and cell viability was measured by MTT
assay. Apoptotic cell death was confirmed by FACS stain for Annexin
V positivity, and by detection of cleavage of caspase-8, caspase-3
and PARP by Western blot. RESULTS: The HCC cell lines
PLC and Hep3b were resistant to treatment with PS-341 or TRAIL
alone, but underwent massive TRAIL-induced apoptosis after pre-
treatment with PS-341. PS-341 markedly increased the molecular
events at different levels of the TRAIL-induced apoptosis signalling
pathway. In contrast, PS-341 could not sensitize primary human
hepatocytes for TRAIL-induced apoptosis. CONCLUSION: Our
data suggest that PS-341 may work by sensitizing HCC for TRAIL-
induced apoptosis without inducing liver cell damage.
15 POSTOPERATIVE PER-ORAL ADMINISTRATION
OF UFT FOR HEPATOCELLULAR CARCINOMA:
PROSPECTIVE, RANDOMIZED STUDY
Kubota K, Nemoto T, Kita J, Shimoda M, Rokkaku K, Kato M,
Sawada T, Dokkyo University School of Medicine, Department
of Gastroenterological Surgery, Tochigi, Japan
INTRODUCTION AND AIM: It has not been clarified how post-
operative adjuvant chemotherapy is effective for preventing recur-
rence of hepatocellular carcinoma (HCC) after resection. The aim
of this study is to prospectively evaluate the effect of per-oral
administration of UFT (5-FU+uracil) for preventing early recur-
rence in relation to thymidylate synthase (TS) and dihydropyrimidine
dehydrogenase (DPD) mRNA expression. PATIENTS AND
METHODS: 81 patients who had undergone curative resection for
HCC (Stages I–III) were assigned to either UFT administration
(400 mg) (Group 1) or UFT non-administration (Group 2) group
according to age (560 or 60–75 years), ICGR15 (520 or 20–40%)
and vp (absent or present) by prospective, randomized method. DPD
and TS gene expression were quantified by TaqMan reverse tran-
scription-PCR assay using fA`-actin as an internal standard and
expressed as TS:fA`-actin or DPD:fA`-actin mRNA ratio in HCCs
and non-cancerous tissues (N-HCCs). RESULTS: There were
34 and 40 patients in groups 1 and 2, respectively, and 7 patients
were excluded from this study due to side effects of UFT. There
were no differences in the ages and ICGR15 between the two
groups. The disease-free rates at 12 months were 68% and 63.5%
in groups 1 and 2, respectively (p=0.31). In group 1 (n=21), the TS
and DPD mRNA were measurable with respective mean values
of 2.43 and 9.63. Although there was no statistically significant
difference, the recurrence rate within 6 months tended to be lower
in 12 patients (group 1A) with low TS (52.43) and low DPD mRNA
(59.63) values than that in 8 patients (group 1B) with high TS
(42.43) and high DPD mRNA (49.63) values (25% vs 50%)
(p=0.25). The disease-free period tended to be longer in group 1A
than in group 1B (15.4 M vs 7.6 M). In group 2, there were no
differences in the recurrence rate within 6 months according to
the TS and DPD mRNA values. CONCLUSION: Postoperative
UFT administration was considered effective for preventing early
recurrence in patients with low TS and low DPD mRNA values
after resection of HCCs.
16 LONG-TERM SURVIVAL OF PATIENTS WITH
ADVANCED (STAGE IV) HCC: RESULTS OF AN
AGGRESSIVE SURGICAL AND SEQUENTIAL COMBINED
THERAPEUTIC APPROACH
Chirica M1, Scatton O1, Massault PP1, Dousset B1, Calmus Y1,
Vignaux O2, Sogni P3, Soubrane O1, (1) Digestive Surgery; (2)
Radiology; (3) Gastroenterology, Hoˆpital Cochin, Fontenay aux
Roses, France
INTRODUCTION AND AIM: The role of surgery in the treatment
of patients with advanced hepatocellular carcinoma (HCC) is still to
define. We report the long-term outcome of patients with stage IV
HCC treated with an aggressive strategy, including initial surgical
resection and local destruction of non-resectable tumors, followed
by complementary treatments (radiofrequency ablation (RFA),
transcatheter arterial chemoembolization (TACE), systemic chemo-
therapy) in case of tumor recurrence. PATIENTS AND
METHODS: Between 1998 and 2004, 20 patients underwent
liver resection for stage IV HCCs. In six patients (30%) local
destruction of non-resectable nodules was associated with liver
resection. Five patients also underwent resection of extrahepatic
tumor. Ten patients had complementary treatments for recurrent
tumor as follows: TACE in six patients (30%), RFA in two patients
(10%) and systemic chemotherapy in three patients (15%).
RESULTS: Postoperative mortality and morbidity were 5% and
30%, respectively. The median number of resected tumors per
patient was 3 (range 1–7), and median diameter of the largest
tumor was 60 mm (range 25–150 mm). With a median follow-up
of 17 months, 14 patients (70%) developed intrahepatic recurrence
and 6 of them also had extrahepatic recurrence. Median survival was
32 months, and the actuarial 1-, 3- and 5-year survival rates were
73%, 56% and 45%. Recurrence-free survival at 3 and 5 years
was 20% and 17%. CONCLUSION: An aggressive therapeutic
approach including a first stage resection and local destruction of
all visible tumors, followed by combined sequential treatment
of recurrence, can result in long-term survival in patients with
stage IV HCC.
17 SURGICAL TREATMENT OF HEPATOCELULLAR
CARCINOMA IN NON-CIRRHOTIC LIVERS
Ardiles V, de Santiban˜es E, Quin˜onez E, Pekolj J, Palavecino M,
Hepato-Pancreato-Biliary Surgery and Liver Transplantation,
Hospital Italiano, Buenos Aires, Argentina
INTRODUCTION AND AIM: Hepatocelullar carcinoma (HCC)
is a primary malignant neoplasm of epithelial liver cells. It is usually
asymptomatic and it is found as an abdominal mass. The aim of
this study is to evaluate the results in patients who underwent a
liver resection for HCC in non-cirrhotic livers. PATIENTS AND
METHODS: Between 1990 and 2003, 1070 hepatectomies were
performed, 44 of which (4.1%) were HCC in non-cirrhotic livers
(41 patients). Postoperative complications, sex, age, risk factors,
preoperative treatments, resection, alpha-fetoprotein, blood trans-
fusion, operative time, Pringle maneuver, associated procedures,
pathological specimen, complications and follow-up were analysed.
RESULTS: Forty-one patients (65.8%) were male, mean age was
46.1 years old (r: 2–77). Mean follow-up was 38.6 months (median:
30). Preoperative procedures were performed in 4 patients. Thirty-
eight (86.3%) were major hepatectomies. The Pringle maneuver
was used in 11 (24.4%). Mean intraoperative blood transfusion was
1.3 units. Mean operative time was 300 minutes, inhospital stay
was 8.9 days, morbidity was 34.1%. Twenty-five patients presented
tumors greater than 5 cm, 5 with vascular invasion. Mean survival
and disease-free survival rates were 70.4% and 52% at 3 years and
58.4% and 38.5% at 5 years, respectively. CONCLUSION: Major
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hepatic resection is a safe procedure when there is appropriate patient
selection; however, 38.9% are disease-free at 3 years.
18 TREATMENT STRATEGY FOR LESS THAN 5 CM
AND SINGLE HEPATOCELLULAR CARCINOMA:
COMPARISON OF RADIOFREQUENCY ABLATION
TREATMENT AND SURGICAL RESECTION
Shimoda M2, Hiraishi H1, Kubota K2, (1) Department of
Gastrointestinal Medicine, Dokkyo University School of Medicine;
(2) Second Department of Surgery, Dokkyo University School of
Medicine, Mibu, Tochigi, Japan
INTRODUCTION AND AIM: This study was conducted to
clarify the efficacy of radiofrequency ablation (RFA) and surgical
resection for the treatment of small hepatocellular carcinoma
(HCC). PATIENTS AND METHODS: From December 2000
to September 2004, 47 patients were treated by RFA (RF group) and
53 patients underwent hepatic resection (Hr group) for small HCC
(smaller than 5 cm, single lesion and no previous treatment).
Retrospectively, 3-year patients and recurrence-free survival rates
were compared between the two groups. Data were expressed as a
mean. Student’s t test and Kaplan-Meier methods were used for
comparisons. A p value 50.05 was considered statistically signifi-
cant. RESULTS: There were no statistically significant differences
with preoperative liver function, gender and age in both groups.
Mean tumor size was 2.2 cm (range 1.0–5.0) in the RF group and
2.4 cm (range 1.0–5.0) in the Hr group, respectively. Mean patient
follow-up was 22.4 months for the RF group and 19.5 months for
the Hr group (p=0.435). In the Hr group, 1- and 3-year overall
survival rates were 96.1% and 91.5%, respectively, while in the RF
group the rates were 97.4% and 84.2%, respectively. There were
no significant differences in both groups (p=0.8663). During the
follow-up period, 12 of the 53 (22.6%) and 15 of the 47 (31.9%)
patients developed tumor recurrence after Hr and RFA. Cumulative
1- and 3-year recurrence- free survival rates in the Hr group were
84.8% and 25.3%, whereas those in the RF group were 74.1% and
62.4%, respectively. CONCLUSION: Our overall findings show
that liver resection can achieve better results overall; however,
RFA had better disease-free survival than liver resection after 3 years.
19 COMPARISON OF HEPATIC RESECTION AND
PERCUTANEOUS ETHANOL INJECTION IN THE
TREATMENT OF SMALL HEPATOCELLULAR CARCINOMA
Cho YB1, Lee KU1, Suh KS1, Kim YJ2, Yoon JH2, Lee HS2, (1)
Department of Surgery; (2) Department of Internal Medicine,
Seoul National University College of Medicine, Seoul, Korea
INTRODUCTION AND AIM: Hepatic resection and percuta-
neous ethanol injection (PEI) are the most widely used curative
therapeutic options for patients with small hepatocellular carcinoma
(HCC). The aim of this study was to clarify the efficacy of each
therapy as an initial treatment for small HCC by comparing the
overall survival and tumor-free survival rate. PATIENTS AND
METHODS: Patients were selected if they met the following criteria:
(i) initial treatment modality, (ii) tumors smaller than or equal to
30 mm, (iii) tumor number less than three, and (iv) Child-Pugh
score A or B. Because of the demographic differences between the
two groups, a propensity score was used to eliminate the influence
of confounding factors and to match the patient population in these
two patient groups. Cox proportional hazard regression was also
performed. RESULTS: Of 1557 patients, 384 were eligible and 174
(87 in each group) were matched one to one based on the propensity
scores. The 1-, 3- and 5-year overall survival rates were 95.4%,
78.0% and 65.0%, respectively, in the resection group; 97.7%,
71.0% and 45.8%, respectively, in the PEI group (p=0.0394).
During the follow-up period, 47 of 87 (54%) and 64 of 87 (74%)
patients developed tumor recurrence after resection and PEI, re-
spectively. The cumulative 1-, 3- and 5-year tumor-free survival rates
in the resection group were 76.6%, 52.2%, and 42.2%, whereas those
in the PEI group were 67.7%, 28.5%, and 22.4%, respectively
(p=0.0028). The hazard ratio for survival of resection versus PEI
was 1.85 (95% CI =1.12–3.06) and that for recurrence was 1.92
(95% CI=1.28–2.86). CONCLUSION: Hepatic resection for small
HCC is a better initial treatment modality than PEI in selected
patients. A prospective randomized study is required to settle this
issue.
20 PERCUTANEOUS RADIOFREQUENCY THERMAL
ABLATION (RFTA) IN THE TREATMENT OF
HEPATOCELLULAR CARCINOMA: A 3-YEAR,
SINGLE-CENTER EXPERIENCE
Zadrozny D1, Sledzinski Z1, Studniarek M2, Adamonis W1,
Gorycki T2, Nowakowski M2, Witczak-Malinowska K3, (1)
Department of General and Endocrine Surgery and
Transplantation, Poland; (2) Department of Radiology; (3)
Department of Infectious Diseases, Medical University of
Gdansk, Gdansk, Poland
INTRODUCTION AND AIM: Hepatocellular carcinoma (HCC)
has become more frequent in western countries. Only a small
proportion of patients can receive curative treatment (liver resection
or transplantation). The prognosis in the untreated group is very
poor with median survival less than 6 months. The aim of this
study was to evaluate safety and efficacy of RFTA in the treatment
of HCC PATIENTS AND METHODS: 57 consecutive patients
(24 F and 33 M) with HCC in cirrhotic liver were treated using
percutaneous RFTA between April 2001 and April 2004. The age
range was 30–81 years (mean 64.5). At the start 83 nodules were
present and ablated (mean 1.46/patient), but due to occurence of
new foci during the whole period 107 tumours were destroyed (mean
1.88/patient) in 102 ablation sessions (1.79 session/patient). In 55
patients liver resection or transplantation was contraindicated, in
one patient RFTA was done as a ‘bridge’ to transplantation, one
patient rejected the proposed surgery. The only contraindication
for RFTA was cancer dissemination. RESULTS: There were 2
intraoperative complications (2%): subcapsular haematoma with
no need for further operation. In two patients liver abscesses were
observed (3.5%), in one it was the cause of fulminant sepsis and early
death (mortality 1.7%). The median survival time in all patients
was 17 months (mean observation time 13.4 months). 1- and 2-year
survival was 64% and 40%, respectively. The main prognostic factor
was the status of primary liver disease; median survival in Child’s A, B
and C groups was more than 36, 24 and 6 months, respectively
(p50.001). CONCLUSION: RFTA is a relatively safe and efficient
method in the treatment of hepatocelullar carcinoma in patients
disqualified from resection/transplantation.
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